Year: 2024
Type: article
Abstract: Immune checkpoint inhibitors have become standard of care for many cancer subtypes. Next generation immuno-oncology (IO) agents are in clinical testing, with thousands of combinations in preclinical evaluation. The success of current and future immunotherapies relies on tools, data and technology to rationalize their use and manage toxicity. However, few biomarkers can distinguish responders from non-responders, predict toxicity, or guide treatment choices.
Source: Immuno-Oncology Technology
Institutions: Royal Marsden Hospital, National Health Service, The Christie NHS Foundation Trust, Institute of Cancer Research, Cancer Research UK Manchester Institute, Wellcome Sanger Institute, The Francis Crick Institute, Cambridge University Hospitals NHS Foundation Trust, Queen Mary University of London, Cancer Research UK, Queen's University Belfast
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,170
OpenAlex ID: W4405374837